Ameriprise Financial Inc. reduced its position in Humana Inc. (NYSE:HUM - Free Report) by 79.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 176,324 shares of the insurance provider's stock after selling 663,020 shares during the period. Ameriprise Financial Inc. owned about 0.15% of Humana worth $44,754,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. grew its stake in shares of Humana by 2.4% during the 3rd quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider's stock valued at $54,047,000 after buying an additional 3,961 shares during the period. Nordea Investment Management AB boosted its position in Humana by 6.6% during the 4th quarter. Nordea Investment Management AB now owns 9,679 shares of the insurance provider's stock worth $2,487,000 after purchasing an additional 602 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Humana by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,848 shares of the insurance provider's stock worth $2,245,000 after purchasing an additional 138 shares during the period. Czech National Bank boosted its position in Humana by 6.4% during the 4th quarter. Czech National Bank now owns 26,108 shares of the insurance provider's stock worth $6,624,000 after purchasing an additional 1,581 shares during the period. Finally, Fiduciary Alliance LLC purchased a new stake in Humana during the 4th quarter worth $1,375,000. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Stock Performance
Shares of NYSE:HUM traded up $6.59 during trading hours on Friday, hitting $234.06. The stock had a trading volume of 818,273 shares, compared to its average volume of 1,699,190. The stock's fifty day simple moving average is $263.20 and its 200 day simple moving average is $269.61. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a market capitalization of $28.25 billion, a price-to-earnings ratio of 23.52, a PEG ratio of 2.05 and a beta of 0.49. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business's revenue was up 8.4% on a year-over-year basis. During the same period last year, the firm posted $7.23 earnings per share. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.51%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is presently 25.04%.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on HUM shares. Robert W. Baird upped their price target on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective on the stock. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $286.81.
View Our Latest Analysis on HUM
Humana Company Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
